Skin cancer is the most commonly diagnosed cancer in the United States — and it's also among the most misunderstood when it comes to life insurance. The critical distinction underwriters make is between non-melanoma skin cancers (basal cell and squamous cell carcinoma) and melanoma. These are treated as entirely different conditions with very different underwriting outcomes. Getting this right before you apply can save you from unnecessary declines and help you access the best available coverage for your situation.

The Critical Distinction: Two Very Different Risk Profiles

When most people hear "skin cancer," they think of a single category. Insurance underwriters think of at least three:

  • Basal Cell Carcinoma (BCC) — The most common skin cancer. Grows slowly, rarely metastasizes, almost always fully resolved by surgical excision. Underwriters treat this as one of the most benign cancer histories possible.
  • Squamous Cell Carcinoma (SCC) — Second most common. Higher metastatic potential than BCC, but still relatively low — approximately 2–5% of SCC cases spread beyond the original site. Stage and involvement determine underwriting outcome significantly.
  • Melanoma — Far less common but significantly more dangerous. Arises from pigment-producing cells (melanocytes), has meaningful metastatic potential, and is responsible for the majority of skin cancer deaths. Underwriters treat melanoma as a serious cancer with outcomes that depend heavily on Breslow thickness, Clark level, sentinel lymph node involvement, and stage at diagnosis.

Basal Cell Carcinoma and Life Insurance

Basal cell carcinoma is treated by most insurers as a resolved condition after successful excision with clear margins. In most cases, a history of BCC — even multiple BCCs — has no effect on your life insurance rate or eligibility. Here's what the typical underwriting process looks like:

  • You disclose your BCC history on the application
  • The underwriter may request pathology reports confirming BCC diagnosis and clear margins
  • In most cases, the BCC history is noted and has no pricing impact
  • Standard rates are available immediately after treatment for most single-site BCC cases
  • Multiple BCCs may prompt additional questions about sun exposure history but typically don't affect pricing

There are exceptions: BCC that invaded deeply into tissue or structures (particularly around the eyes, nose, or ears where surgical margins are difficult), or BCC that has recurred multiple times, may receive more scrutiny. But these are uncommon scenarios. For the vast majority of BCC survivors, life insurance is straightforwardly available at standard rates with no waiting period.

Squamous Cell Carcinoma and Life Insurance

SCC is generally also treated favorably by life insurance underwriters, though with slightly more nuance than BCC:

Low-Risk SCC (Superficial, No Lymph Node Involvement)

In situ SCC (Bowen's disease) and superficial SCC with complete excision and clear margins are typically treated similarly to BCC — standard rates available after confirmed treatment. These represent the majority of SCC diagnoses.

Higher-Risk SCC Features

Underwriters pay closer attention to SCC with any of the following characteristics:

  • Tumor larger than 2 cm in diameter
  • Located on the ear, lip, or around the eye (anatomically challenging excision sites)
  • Perineural invasion (cancer cells along nerve sheaths)
  • Lymphovascular invasion
  • Regional lymph node involvement
  • Immunocompromised patient (transplant recipients, those on immunosuppressants)

High-risk SCC with any of these features typically requires a waiting period of 1–3 years and may result in table ratings at some carriers. SCC with lymph node involvement is treated more seriously — underwriting approaches that of early-stage melanoma in terms of waiting periods and scrutiny.

Melanoma and Life Insurance: The Full Picture

Melanoma is where underwriting complexity begins in earnest. The outcome depends on multiple pathological factors that underwriters evaluate in detail.

Key Factors Underwriters Evaluate for Melanoma

Breslow Thickness

The depth of melanoma invasion into the skin, measured in millimeters. This is the single most important prognostic factor for melanoma and the one underwriters focus on most heavily:

  • In situ (Clark Level I) — Confined to the epidermis, no invasion depth. Essentially no metastatic risk. Many carriers treat this identically to BCC — standard rates, no waiting period.
  • Under 0.8 mm (T1a) — Thin melanoma without ulceration. Excellent prognosis. Standard rates typically available after 1–2 years at most carriers, sometimes sooner.
  • 0.8–1.0 mm (T1b) — Thin with ulceration or mitotic rate ≥1/mm². Slightly higher recurrence risk. Most carriers require 1–3 years of clean follow-up.
  • 1.0–2.0 mm (T2) — Intermediate thickness. Meaningful recurrence risk increases. Most carriers require 3–5 years of clean surveillance before offering standard or near-standard rates.
  • 2.0–4.0 mm (T3) — Thicker lesion. Significant recurrence risk. Most carriers require 5–7 years of clean follow-up. Table ratings are common even at 5 years. Some carriers offer simplified issue rather than fully underwritten coverage during this period.
  • Over 4.0 mm (T4) — Thick lesion with highest local recurrence risk. Most carriers require 7–10 years of confirmed remission. Standard coverage may not be available at some carriers even after this period.

Clark Level

A companion staging measure to Breslow thickness, describing the anatomical layer invaded:

  • Level I (epidermis only) — In situ, treated as described above
  • Level II (papillary dermis) — Often corresponds to thin Breslow measurements; generally favorable
  • Level III (fills papillary dermis) — Moderate concern
  • Level IV (reticular dermis) — Significant concern, adds to Breslow thickness concerns
  • Level V (subcutaneous tissue) — Most serious local invasion; treated similarly to thick Breslow measurements

Ulceration

Ulceration (breakdown of the overlying skin) at the melanoma site is an independent risk factor that upgrades staging even for thin lesions. A melanoma under 0.8 mm Breslow thickness without ulceration (T1a) is treated more favorably than one of the same thickness with ulceration (T1b). Underwriters ask specifically about ulceration because it meaningfully increases recurrence and metastasis risk.

Sentinel Lymph Node Biopsy Results

For melanomas over 0.8 mm Breslow thickness, a sentinel lymph node biopsy is typically performed to check for spread to regional lymph nodes. This result is critical:

  • Sentinel lymph node negative (N0) — No regional spread confirmed. This is the most favorable outcome and the basis for the waiting period framework described above.
  • Sentinel lymph node positive (N1 or higher) — Regional spread to lymph nodes confirmed. This fundamentally changes the underwriting outcome. Node-positive melanoma is Stage III disease, and standard coverage is very difficult to access within 5–7 years of treatment. Simplified issue or guaranteed issue is the realistic path in the near term.

Stage at Diagnosis

  • Stage 0 (in situ) — Standard rates typically available immediately or after 1–2 years
  • Stage I (thin, node-negative) — Standard rates typically available after 1–3 years at most carriers
  • Stage II (thicker, node-negative) — Standard rates typically available after 3–7 years depending on substage and Breslow thickness
  • Stage III (any thickness, node-positive) — Standard coverage generally not available within 5 years; table ratings or simplified issue for extended period
  • Stage IV (distant metastasis) — Standard coverage not typically available; guaranteed issue is the realistic option

Acral Lentiginous and Mucosal Melanoma

These are rarer subtypes that occur on palms, soles, nail beds, and mucous membranes. Underwriting follows the same Breslow/staging framework as cutaneous melanoma but may receive additional scrutiny due to their less common nature and sometimes later-stage diagnosis.

Follow-Up Surveillance and Its Role in Underwriting

For melanoma survivors, documented surveillance history is one of the strongest signals you can provide to underwriters. Dermatology follow-up visits with clean skin checks, imaging results, and laboratory findings (LDH levels for Stage II and above) all contribute to a stronger application. Specific things to document:

  • Frequency of dermatology follow-up visits and dates
  • Results of any imaging (PET, CT, MRI) ordered during surveillance
  • LDH and other relevant biomarker results
  • Any new lesion biopsies with results

Gaps in surveillance — months or years without follow-up — are a negative signal for underwriters. Even if you felt well and your physician agreed close surveillance wasn't urgent, gaps in the record create uncertainty about what may have been missed. Staying current with follow-up appointments is both medically and financially important.

Policy Options by Situation

Non-Melanoma (BCC/SCC) Survivors

Standard life insurance at standard rates, typically with no waiting period after treatment. Disclose your history honestly, provide pathology records if requested, and apply through normal channels. An independent broker can confirm which carriers are most efficient with BCC/SCC applications.

Melanoma In Situ or Stage I (Thin, Node-Negative)

Standard coverage available at most carriers after 1–3 years. Apply through an independent broker who can identify which carriers are most favorable for early-stage melanoma. Table ratings are possible in the first 1–2 years but should improve as surveillance time accumulates.

Stage II Melanoma

Fully underwritten coverage available after 3–7 years at most carriers. Simplified issue policies are available during the waiting period. Work with an impaired-risk specialist broker — carrier guidelines for Stage II melanoma vary significantly, and the right carrier can make a meaningful difference in both availability and rate.

Stage III or IV Melanoma

Standard fully underwritten coverage is generally not accessible in the near term. Options during the waiting period: simplified issue (limited face amounts), graded benefit policies, and guaranteed issue. Group life insurance through an employer is often the best available coverage during this period. Long-term, Stage III survivors who achieve 7–10 years of confirmed complete remission may find specialty carriers willing to consider a fully underwritten application.

How to Strengthen Your Application

  1. Gather complete pathology documentation. The pathology report from your original excision, sentinel node biopsy results (if performed), and surveillance records are the core of your application. Underwriters reviewing melanoma cases need this detail to make accurate decisions.
  2. Stay current with dermatology follow-up. Consistent surveillance with clean results is the strongest signal you can build over time. Don't skip follow-up appointments.
  3. Work with an impaired-risk specialist broker. Melanoma underwriting varies more between carriers than almost any other cancer type. The right broker knows which carriers are most favorable for your specific Breslow thickness, stage, and time elapsed.
  4. Apply when your timing is strongest. If you're approaching a meaningful milestone (3 years, 5 years, 7 years), wait until you cross it before applying — the rate difference can be significant.
  5. Optimize everything you can control. Non-smoker status, healthy BMI, and well-managed other health conditions all help offset the melanoma history in the overall risk assessment.

Related Guides in This Series

Bottom Line

Skin cancer is not a single underwriting category. Basal cell carcinoma survivors can almost always get standard life insurance immediately after treatment. Squamous cell carcinoma survivors face only slightly more complexity in most cases. Melanoma survivors face a process that depends heavily on Breslow thickness, staging, and surveillance history — but meaningful coverage is available for most early-stage survivors, and options improve steadily as remission time accumulates. Understanding where your specific situation falls before you apply sets accurate expectations and puts you in a position to access the best available coverage.

This content is for informational purposes only and does not constitute insurance, financial, or legal advice. Insurance options vary by carrier, state, and individual health history. Always consult a licensed insurance professional before making coverage decisions.